Get notified of page updates
Androgen Suppression With Abiraterone, Leuprolide, PARP Inhibitor and Stereotactic Radiotherapy in Prostate Cancer (ASCLEPIuS)
Newly diagnosed prostate cancer grade group 3-5
Clinicaltrials.gov identifier:NCT04194554
Glossary on
off
About the Study
This study is no longer enrolling patients.
This study will look at treating men with high risk cancer using the , combined with stereotactic body radiotherapy (SBRT), , leuprolide, and prednisone. Phase 1 of this study will look at the best dose of for this treatment combination. The phase 2 portion of this study will look at the 3-year recurrence free-survival rate of the patients who received this combined therapy.
This Study is Open To:
This study is no longer enrolling patients.
This Study is NOT Open To:
This study is no longer enrolling patients.
Newly diagnosed prostate cancer grade group 3-5
Clinicaltrials.gov identifier:NCT04194554